Although, after watching his channel for a half hour, he isn’t letting it hold him back from bringing smiles to millions of faces.
Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI, or MPS6, is caused by an enzyme deficiency. One of the most visible signs of MPS6 is short stature, but there is a broad spectrum or disabilities associated with this syndrome.
Unfortunately, skeletal abnormalities are progressive, particularly in the pelvic region, causing the person to have a hunched-over posture.
Finally, there is a treatment in the form of an enzyme replacement that holds promise for improving joint function.
The only catch? Naglazyme is among the most expensive drugs in the United States with costs coming in around $365,000 dollars a year.
But, before you lose all faith in the pharmaceutical industry, remember that it’s enormously expensive to develop a new drug, test it in clinical trials, and then bring it to market. Also, considering how rare MPS6 is, the fact that a treatment has been approved by the FDA is nothing short of a miracle.
BioMarin, the maker of Naglazyme also has a Compassionate Use policy to help patients afford the treatment.
Well played, Keenan!